The evaluation of protective and mitigating effects of vitamin C against side effects induced by radioiodine therapy

Abstract

The goal of this study was to evaluate the protective and mitigative effect of vitamin C on oxidative stress in differentiated thyroid cancer (DTC) patients ablated with radioiodine. 58 DTC patients selected for radioactive iodine therapy (RAIT) with 5550 MBq Iodine were divided into four groups. Group 1 (control group) consisted of patients who underwent RAIT routinely. Other patients received 1500 mg vitamin C daily 2 days after (group 2), 2 days before to 2 days after (group 3) and 2 days before RAIT (group 4). Serum oxidative stress markers including malondialdehyde (MDA), glutathione (GSH), catalase (CAT), and superoxide dismutase (SOD) were measured immediately before and 2 days after RAIT. A significant increase in MDA after RAIT was observed in all groups (p< 0.05). The concentrations of MDA were significantly higher in the control group compared to the intervention groups (p < 0.05). A significant decrease in the control group (p < 0.05) and increase in group 4 (p < 0.05) were observed in GSH level after RAIT (p < 0.05). Mean variation of GSH was significant between control group with groups 3 (p < 0.01) and 4 (p < 0.01). The results indicate that activity of SOD remained unchanged in all groups (p > 0.05). A significant increase was observed in CAT activity after RAIT in all groups (p < 0.05), which was higher in control group than intervention groups. In groups 3 (p < 0.05) and 4 (p < 0.05), this increase in CAT activity was significantly lower than the control group. RAIT causes serum oxidative stress, which can be ameliorated using vitamin C as an antioxidant. These results indicate that radioprotective effect of vitamin C is preferable to its mitigative effect.

Study logistics that can impact medical countermeasure efficacy testing in mouse models of radiation injury

“…;Kanter and Akpolat 2008;Satyamitra et al 2011;Mortazavi et al 2015;Roche et al 2015;Zangeneh et al 2015;Rostami et al 2016;Alexander et al 2018;Jafari et al 2018), vitamin D(Langberg et al 2009;Gavrilov et al 2010;Marampon et al 2016) and vitamin E(Ross et al 1983;Shaheen and Hassan 1991;Empey et al 1992;Nair et al 2003; Satyamitra et al…”

Antioxidant vitamins promote anticancer effects on low‐concentration methotrexate‐treated glioblastoma cells via enhancing the caspase‐3 death pathway

“…Vitamin C has antioxidant activities. Many studies have demonstrated that vitamin C can decrease oxidative stress against chemical therapy‐induced side effects for various cancer treatments (Jafari et al., 2018; Klimant et al., 2018; Vollbracht et al., 2011). Previous studies have also used vitamin C as an adjuvant drug for GBM treatment to decrease cancer therapy‐related side effects (Baillie et al., 2018; Rodríguez et al., 2013).…”

Microfluidization trends in the development of nanodelivery systems and applications in chronic disease treatments

“…Cancer is among the major chronic diseases that cause major human death throughout the world, and scientists work diligently to produce various drugs for its treatment. [140][141][142] General medical practice includes radiation and chemotherapy, which lead to various other complications leading the patients in much stress. [143][144][145] Recently, nanomedicine has played a vital role in the treatment of cancer overcoming several side effects of traditional medicines, although nanodelivery systems loaded with drugs or plant-based bioactive compounds face critical challenges in the delivery of the bioactive compounds to the target sites and through the delivery systems.…”